Publications by authors named "Rolf Bohlmann"

Claim this Profile
C
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Philip Lienau, Gerhard Siemeister, Rolf Bohlmann

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
Volker K Schulze, Ulrich Klar, Dirk Kosemund, Antje M Wengner, Gerhard Siemeister, Rolf Bohlmann

J Med Chem· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Rolf Bohlmann

ChemMedChem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
Ingo V Hartung, Stefanie Hammer, Marion Hitchcock, Roland Neuhaus, Arne Scholz, Rolf Bohlmann

Bioorg Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro.
Christiane Otto, Iris Fuchs, Helga Altmann, Mario Klewer, Gilda Schwarz, Rolf Bohlmann

J Steroid Biochem Mol Biol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a radioimmunoassay for the quantitative determination of 8-prenylnaringenin in biological matrices.
Olaf Schaefer, Rolf Bohlmann, Wolf-Dieter Schleuning, Kai Schulze-Forster, Michael Hümpel

J Agric Food Chem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Jens Hoffmann, Rolf Bohlmann, Nikolaus Heinrich, Helmut Hofmeister, Jörg Kroll

J Natl Cancer Inst· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8-Prenyl naringenin is a potent ERalpha selective phytoestrogen present in hops and beer.
Olaf Schaefer, Michael Hümpel, Karl-Heinrich Fritzemeier, Rolf Bohlmann, Wolf-Dieter Schleuning

J Steroid Biochem Mol Biol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis